X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. Disodium Terephthalate
2. Terephthalate
1. 100-21-0
2. P-phthalic Acid
3. 1,4-benzenedicarboxylic Acid
4. Benzene-1,4-dicarboxylic Acid
5. P-dicarboxybenzene
6. P-benzenedicarboxylic Acid
7. P-carboxybenzoic Acid
8. Acide Terephtalique
9. Tephthol
10. 1,4-dicarboxybenzene
11. Kyselina Tereftalova
12. Wr 16262
13. Ta-33mp
14. 4-carboxybenzoic Acid
15. Nsc 36973
16. Hsdb 834
17. P-phthalate
18. Ta 12
19. Kyselina Terftalova
20. Benzene-p-dicarboxylic Acid
21. 6s7nkz40bq
22. Chebi:15702
23. Nsc-36973
24. Para-phthalic Acid
25. Dsstox_cid_6080
26. Dsstox_rid_78007
27. Dsstox_gsid_26080
28. Acide Terephtalique [french]
29. Kyselina Tereftalova [czech]
30. Cas-100-21-0
31. Ccris 2786
32. Einecs 202-830-0
33. Unii-6s7nkz40bq
34. Ecamsule Related Compound C
35. Brn 1909333
36. Terephtalic Acid
37. Ai3-16108
38. P-phthelate
39. P-phthelic Acid
40. Ub7
41. Mfcd00002558
42. P-benzenedicarboxylate
43. Terephthalsäure
44. Benzene-p-dicarboxylate
45. Benzene-1,4-dioic Acid
46. Wln: Qvr Dvq
47. Terephthalic Acid, 97%
48. Terephthalic Acid, 98%
49. Ec 202-830-0
50. Schembl1655
51. Para-benzenedicarboxylic Acid
52. Benzene, P-dicarboxylic Acid
53. 4-09-00-03301 (beilstein Handbook Reference)
54. Bidd:er0245
55. Tere-phthalic Acid (sublimed)
56. Terephthalic Acid [mi]
57. Chembl1374420
58. Dtxsid6026080
59. Terephthalic Acid [hsdb]
60. Benzene, 1,4-dicarboxylic Acid
61. P-dicarboxybenzene P-phthalic Acid
62. Bcp06429
63. Nsc36973
64. Str02759
65. Tox21_201659
66. Tox21_303229
67. S6251
68. Stl281856
69. Zinc12358714
70. Ecamsule Related Compound C Rs
71. Terephthalic Acid, Analytical Standard
72. Akos000119464
73. Cs-w010814
74. Hy-w010098
75. Ncgc00091618-01
76. Ncgc00091618-02
77. Ncgc00091618-03
78. Ncgc00257014-01
79. Ncgc00259208-01
80. Ac-10250
81. Bp-21157
82. Ecamsule Related Compound C [usp-rs]
83. Ft-0674866
84. Ft-0773240
85. T0166
86. Terephthalic Acid 100 Microg/ml In Methanol
87. C06337
88. Terephthalic Acid, Saj Special Grade, >=98.0%
89. A852800
90. Ae-562/40217759
91. Ecamsule Related Compound C [usp Impurity]
92. Q408984
93. Terephthalic Acid, Vetec(tm) Reagent Grade, 98%
94. Z57127536
95. Kyselina Terftalova, Rarechem Al Bo 0011, 1,4-phthalicacid
96. Ecamsule Related Compound C, United States Pharmacopeia (usp) Reference Standard
| Molecular Weight | 166.13 g/mol |
|---|---|
| Molecular Formula | C8H6O4 |
| XLogP3 | 2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 2 |
| Exact Mass | 166.02660867 g/mol |
| Monoisotopic Mass | 166.02660867 g/mol |
| Topological Polar Surface Area | 74.6 Ų |
| Heavy Atom Count | 12 |
| Formal Charge | 0 |
| Complexity | 169 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Free Radical Scavengers
Substances that eliminate free radicals. Among other effects, they protect PANCREATIC ISLETS against damage by CYTOKINES and prevent myocardial and pulmonary REPERFUSION INJURY. (See all compounds classified as Free Radical Scavengers.)
... The concentrations of urine terephthalic acid(TPA) in rats after single oral administration in dose of 100 mg/kg bw were determined by high pressure liquid chromatography. ... The results showed that the first-order kinetics and two-compartment model were noted on the elimination of TPA. ... The excretion rates of TPA in urine were about 50%, 52% and 53% in 0-24 hr, 0-48 hr and 0-72 hr respectively after administration. TPA is well absorbed when given orally and rapidly eliminated via urine. Urine TPA at the end of work shift should be considered as a biomarker of exposure for the occupational workers.
PMID:11255755 Yao H et al; Wei Sheng Yan Jiu. 30 (1): 23-4 (2001)
Terephthalic acid is absorbed from the gastrointestinal tract and is excreted in the urine apparently unchanged. Dermal or ocular absorption is negligible.
Organization for Economic Cooperation and Development; Screening Information Data Set for Terephthalic Acid, (100-21-0) p.14 (June 2001). Available from, as of October 18, 2011: https://www.inchem.org/pages/sids.html
The pharmacokinetics of (14)C terephthalic acid were determined in Fischer-344 rats after iv and oral administration. After iv injection, the plasma concentration-time data were fitted with a three-compartment pharmacokinetic model. The average terminal half-life in 3 rats was 1.2 + or - 0.4 hr, and the average volume of distribution in the terminal phase was 1.3 + or - 0.3 l/kg. Following administration by gavage, a longer terminal half-life was obtained, indicating that dissolution of (14)C TPA or absorption from the gut may have been partially rate limiting. Recovery of (14)C TPA in the urine following a bolus iv dose was 101 + or - 8%, indicating essentially complete urinary excretion of the compound. No evidence of metabolism of (14)C TPA was obtained by analysis of urine by high-performance liquid chromatography. (14)C TPA was transported to the fetus after administration of the compound to pregnant rats; the concentrations in fetal tissues were low relative to the corresponding maternal tissues. Neonatal rats exposed to 5% TPA in the diet of their dams did not develop calculi until the onset of self-feeding. TPA was rapidly excreted into urine after administration to rats, and excretory mechanisms in the dam provided an effective mechanism of defense against TPA-induced urolithiasis in neonatal rats.
PMID:6128197 Wolkowski-Tyl R et al; Drug Metab Dispos 10 (5): 486-90 (1982)
By use of the Sperber in vivo chicken preparation method, infusion of radiolabeled terephthalic acid ([14C]TPA) into the renal portal circulation revealed a first-pass excretion of the unchanged compound into the urine. This model was utilized further to characterize the excretory transport of [14C]TPA and provide information on the structural specificity in the secretion of dicarboxylic acids. At an infusion rate of 0.4 nmol/min. 60% of the [14C]TPA which reached the kidney was directly excreted. An infusion rate of 3 or 6 mumol/min resulted in complete removal of [14C]TPA by the kidney. These results indicate that TPA is both actively secreted and actively reabsorbed when infused at 0.4 nmol/min and that active reabsorption is saturated with the infusion of TPA at higher concentrations. The secretory process was saturated with the infusion of TPA at 40 mumol/mn. The excretory transport of TPA was inhibited by the infusion of probenecid, salicylate, and m-hydroxybenzoic acid, indicating that these organic acids share the same organic anion excretory transport process. m-Hydroxybenzoic acid did not alter the simultaneously measured excretory transport of p-aminohippuric acid (PAH), suggesting that there are different systems involved in the secretion of TPA and PAH. The structural specificity for renal secretion of dicarboxylic acids was revealed by the use of o-phthalic acid and m-phthalic acid as possible inhibitors of TPA secretion. m-Phthalate, but not o-phthalate, inhibited TPA excretory transport, indicating that there is some specificity in the renal secretion of carboxy-substituted benzoic acids. TPA was actively accumulated by rat and human cadaver renal cortical slices.
PMID:3966238 Tremaine LM, Quebbemann AJ; Toxicol Appl Pharmacol 77 (1): 165-74 (1985)
(14)C-Labeled terephthalic acid may be both secreted and reabsorbed by the nephron, and when infused at 3 or 6 umol/min its excretion efficiency is comparable to that of p-aminohippuric acid and tetraethylammonium.
Quebbemann AJ et al; Monogr Appl Pharm (Nephrotoxicity) (1): 113-6 (1982)
A Rhodococcus species was isolated from soil by enriching for growth with dimethyl terephthalate as the sole carbon source. The organism degraded dimethyl terephthalate by hydrolysis of ester-bonds to free terephthalic acid which in turn was metabolized through protocatechuate by an ortho-cleavage pathway.
Ninnekar HZ, Pujar BG; Ind J Biochem Biophys 22 (4): 232-5 (1985)
No evidence of metabolism of (14)C TPA was obtained by analysis of urine by high-performance liquid chromatography /following an iv dose to Fischer-344 rats/.
PMID:6128197 Wolkowski-Tyl R et al; Drug Metab Dispos 10 (5): 486-90 (1982)
... The concentrations of urine terephthalic acid(TPA) in rats after single oral administration in dose of 100 mg/kg bw were determined by high pressure liquid chromatography. ... The results showed that the first-order kinetics and two-compartment model were noted on the elimination of TPA. The main toxicokinetic parameters were as follows: Ka = 0.51/hr, half-life ka = 0.488 hr, half-life alpha = 2.446 hr, time to peak = 2.160 hr, Ku = 0.143/hr, half-life beta = 31.551 hr, Xu(max) = 10.00 mg. ...
PMID:11255755 Yao H et al; Wei Sheng Yan Jiu. 30 (1): 23-4 (2001)
The pharmacokinetics of (14)C labeled terephthalic acid were determined in Fischer 344 rats after iv and oral administration. After iv injection, the plasma concentration-time data were fitted using a 3-compartment pharmacokinetic model. The avg terminal half-life in rats was 1.2 hr and the average volume of distribution in the terminal phase was 1.3 L/kg.
PMID:6128197 Wolkowski-Tyl R et al; Drug Metab Dispos 10 (5): 486-90 (1982)
(14)C-Terephthalic acid has a short elimination half-life (approximately 60-100 minutes) in the plasma; however, the apparent half-life was longer following administration by gavage.
Organization for Economic Cooperation and Development; Screening Information Data Set for Terephthalic Acid, (100-21-0) p.14 (June 2001). Available from, as of October 18, 2011: https://www.inchem.org/pages/sids.html
/The aim of this study was/ to investgate the metabolism of terephthalic acid (TPA) in rats and its mechanism. Metabolism was evaluated by incubating sodium terephthalate (NaTPA) with rat normal liver microsomes, or with microsomes pretreated by phenobarbital sodium, or with 3-methycholanthrene, or with diet control following a NADPH-generating system. The determination was performed by high performance liquid chromatography (HPLC), and the mutagenic activation was analyzed by umu tester strain Salmonella typhimurium NM2009. Expression of CYP4B1 mRNA was detected by RT-PCR. The amount of NaTPA (12.5-200 uL /per/ L) detected by HPLC did not decrease in microsomes induced by NADPH-generating system. Incubation of TPA (0.025-0.1 mmol /per/ L) with induced or noninduced liver microsomes in an NM2009 umu response system did not show any mutagenic activation. TPA exposure increased the expression of CYP4B 1 mRNA in rat liver, kidney, and bladder. Lack of metabolism of TPA in liver and negative genotoxic data from NM2009 study are consistent with other previous short-term tests...
PMID:16673812 Dai GD et al; Biomed Environ Sci 19 (1): 8-14 (2006)
Market Place
